Platelet aggregation and plasma components

Platelet aggregation and plasma components represent the integrated physiological systems responsible for hemostasis and the prevention of blood loss (StatPearls, 2023). Platelet aggregation is the process by which platelets adhere to one another and the vascular wall at sites of injury, a process primarily mediated by receptors such as glycoprotein IIb/IIIa and P2Y12 (NIH, 2022). Plasma components include the various clotting factors and proteins, such as fibrinogen and thrombin, that constitute the coagulation cascade, ultimately forming a stable fibrin mesh (Merck Manual, 2023). While essential for survival, dysregulation of these components can lead to pathological thrombosis, resulting in conditions like myocardial infarction, ischemic stroke, and deep vein thrombosis (PubMed, 2021). Pharmacological agents targeting this system are broadly classified into antiplatelet drugs, which inhibit platelet activation, and anticoagulants, which target specific enzymatic steps in the plasma coagulation cascade (NCBI, 2023). Clinical management of these targets requires balancing the prevention of thrombotic events with the inherent risk of major bleeding or hemorrhage (StatPearls, 2023). This broad category encompasses multiple distinct molecular targets rather than a single receptor or enzyme, making it a functional or phenotypic classification in drug development.

Other names

HemostasisBlood coagulation systemThrombosis and hemostasisBlood clotting system

Drugs targeting this system act by inhibiting platelet activation and aggregation (e.g., via P2Y12 receptor antagonism or COX-1 inhibition) or by interfering with the coagulation cascade in the plasma (e.g., via Factor Xa or thrombin inhibition) (StatPearls, 2023; NCBI, 2023).